Maravai LifeSciences Holdings, Inc.
MRVIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMaravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North. At a $2.66B market cap, Maravai LifeSciences Holdings, Inc. ranks as a mid-cap company within healthcare. It operates through two segments: TRILINK and CYGNUS.
Market Cap
$2.66B
Beta
0.60
P/E (TTM)
—
P/E (Fwd)
-71.62
EPS (TTM)
$-0.53
EPS (Fwd)
$-0.10
ROE
-33.1%
ROA
-5.7%
Cash
$70.1M
Total Debt
$218.1M
Free CF
-$3.6M
52W Change
181.5%
Annual Financials
Cash vs Debt
Where MRVI stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, MRVI finished 55.37% above its 150-day moving average ($4.75) and 65.10% above its 200-day moving average ($4.47). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MRVI overbought or oversold?
At the September 3, 2026 close, MRVI's RSI(14) was 64.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, MRVI has $70.1M in cash with $218.1M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$3.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -33.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $883.0M (2022) to $185.7M (2025), a 79% decline worth watching.
MRVI's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MRVI.